Veru (NASDAQ:VERU) Coverage Initiated by Analysts at Raymond James

Equities research analysts at Raymond James began coverage on shares of Veru (NASDAQ:VERU - Get Free Report) in a research note issued on Thursday, MarketBeat.com reports. The brokerage set an "outperform" rating and a $3.00 price target on the stock. Raymond James' target price indicates a potential upside of 328.51% from the company's previous close.

Separately, HC Wainwright restated a "buy" rating and set a $2.00 price target on shares of Veru in a report on Thursday, February 8th.

Veru Stock Up 8.3 %

Shares of NASDAQ:VERU traded up $0.05 on Thursday, hitting $0.70. 5,911,512 shares of the company traded hands, compared to its average volume of 1,848,649. Veru has a 52 week low of $0.36 and a 52 week high of $1.52. The stock has a 50 day simple moving average of $0.53 and a 200-day simple moving average of $0.73. The company has a market cap of $96.35 million, a PE ratio of -0.62 and a beta of -0.23.

Institutional Investors Weigh In On Veru

Several institutional investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in shares of Veru by 33.1% during the fourth quarter. Vanguard Group Inc. now owns 4,709,876 shares of the company's stock valued at $3,391,000 after buying an additional 1,171,033 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Veru during the fourth quarter valued at $72,000. Perceptive Advisors LLC boosted its position in shares of Veru by 412.4% during the fourth quarter. Perceptive Advisors LLC now owns 5,584,699 shares of the company's stock valued at $4,021,000 after buying an additional 4,494,821 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Veru by 150.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 63,300 shares of the company's stock valued at $46,000 after buying an additional 38,000 shares during the last quarter. Finally, Potomac Capital Management Inc. purchased a new stake in shares of Veru during the fourth quarter valued at $471,000. 47.16% of the stock is owned by hedge funds and other institutional investors.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.